Analyzing...
Loading company...
5 forward guidance items shared
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹27,548 Cr revenue.
COGS 32.4%, employees 17.5%.
“zero to six months...two big respiratory launches...expect to be the sole generic in those for a substantial period of time”
“two products...could be one of the largest products for the company...ballpark in that top two or top three product type of a profile for revenue”
“quarterly revenue of INR 7,074 crore, which is flat Y o Y.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | - | - |
| ROCE | - | - |
| Net Margin | - | - |
| EBITDA Margin | - | - |
| Debt To Equity | - | - |
| Current Ratio | - | - |
| Rev Growth 3yr | - | - |
| EPS Growth 3yr | - | - |
| Asset Turnover | - | - |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2025 | FY2024 | FY2024 | FY2023 | FY2023 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Other Income | ₹1,023 Cr +18.7% | ₹862 Cr 0.0% | ₹862 Cr +15.4% | ₹747 Cr 0.0% | ₹747 Cr +57.0% | ₹475 Cr 0.0% | ₹475 Cr +69.3% | ₹281 Cr |
| Total Income | ₹29,374 Cr +3.4% | ₹28,409 Cr 0.0% | ₹28,409 Cr +7.1% | ₹26,521 Cr 0.0% | ₹26,521 Cr +14.2% | ₹23,229 Cr 0.0% | ₹23,229 Cr +5.4% | ₹22,044 Cr |
| COGS | ₹9,489 Cr +6.3% | ₹8,929 Cr 0.0% | ₹8,929 Cr +1.2% | ₹8,820 Cr 0.0% | ₹8,820 Cr +6.9% | ₹8,252 Cr 0.0% | ₹8,252 Cr -2.9% | ₹8,496 Cr |
| ₹23,078 Cr +6.9% | ₹21,589 Cr 0.0% | ₹21,589 Cr +4.7% | ₹20,624 Cr 0.0% | ₹20,624 Cr +8.5% | ₹19,008 Cr 0.0% | ₹19,008 Cr +3.5% | ₹18,369 Cr | |
| Profit Before Tax | ₹6,021 Cr -11.7% | ₹6,821 Cr 0.0% | ₹6,821 Cr +19.6% | ₹5,702 Cr 0.0% | ₹5,702 Cr +41.2% | ₹4,038 Cr 0.0% | ₹4,038 Cr +15.6% | ₹3,493 Cr |
| Exceptional Items | (₹276 Cr) | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹195 Cr) 0.0% | (₹195 Cr) -6.8% | (₹182 Cr) 0.0% | (₹182 Cr) -0.2% | (₹182 Cr) |
| ₹1,476 Cr -3.5% | ₹1,530 Cr 0.0% | ₹1,530 Cr -1.1% | ₹1,547 Cr 0.0% | ₹1,547 Cr +28.6% | ₹1,203 Cr 0.0% | ₹1,203 Cr +28.8% | ₹934 Cr | |
| Net Profit | ₹4,533 Cr -14.0% | ₹5,269 Cr 0.0% | ₹5,269 Cr +26.9% | ₹4,154 Cr 0.0% | ₹4,154 Cr +46.6% | ₹2,833 Cr 0.0% | ₹2,833 Cr +11.2% | ₹2,547 Cr |
| Profit (Owners) | ₹4,546 Cr -13.8% | ₹5,273 Cr 0.0% | ₹5,273 Cr +27.9% | ₹4,122 Cr 0.0% | ₹4,122 Cr +47.1% | ₹2,802 Cr 0.0% | ₹2,802 Cr +11.3% | ₹2,517 Cr |
| Minority Interest | (₹13 Cr) -293.4% | (₹3 Cr) 0.0% | (₹3 Cr) ↓ Decline | ₹32 Cr 0.0% | ₹32 Cr +3.8% | ₹31 Cr 0.0% | ₹31 Cr +3.6% | ₹30 Cr |
| Other Comprehensive Income | ₹606 Cr +177.3% | ₹219 Cr 0.0% | ₹219 Cr ↑ Recovery | (₹121 Cr) 0.0% | (₹121 Cr) ↓ Decline | ₹138 Cr 0.0% | ₹138 Cr -64.1% | ₹384 Cr |
| EPS | ₹56.29 | ₹65.28 | ₹65.28 | ₹51.05 | ₹51.05 | ₹34.71 | ₹34.71 | ₹31.19 |
| Diluted Shares | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr | ₹81 Cr |
| Profit Or Loss Of Associates | (₹11 Cr) +48.1% | (₹22 Cr) 0.0% | (₹22 Cr) | (₹2 Cr) 0.0% | (₹2 Cr) +38.8% | (₹3 Cr) 0.0% | (₹3 Cr) +79.7% | (₹13 Cr) |
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Cipla receives U.S. FDA approval for first AB Rated Generic of Ventolin® HFA
Cipla Limited has informed the Exchange about USFDA inspection at Company's manufacturing facility in Goa, India
Cipla Limited has informed the Exchange about newspaper publication regarding Second 100-day Campaign 'Saksham Niveshak'
Cipla Limited has informed the Exchange about Copy of Newspaper Publication
Cipla Limited has informed the Exchange regarding Notice of Postal Ballot
Cipla Limited has informed the Exchange regarding 'Update on US Food and Drug Administration (USFDA) inspection on Pharmathen International S.A. '.
Cipla Limited has informed the Exchange about Schedule of meet
Cipla Limited has informed the Exchange about General Updates
Cipla Limited has informed the Exchange about General Updates
Cipla Limited has informed the Exchange about General Updates
Cipla Limited has informed the Exchange about Schedule of meet
Cipla Limited has informed the Exchange about change in Management
Cipla Limited has informed the Exchange regarding allotment of 8879 securities pursuant to ESOP/ESPS at its meeting held on January 28, 2026
Cipla Limited has informed the Exchange about Transcript
Cipla Limited has informed the Exchange about Copy of Newspaper Publication